welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Shattering Cancer with Resonant Frequencies: Anthony Holland at TEDx Skidmore Collegehttps://www.youtube.com/watch?v=1w0_kazb...
Ileal Pouch-Anal Anastomosis RegistryLittle is known about the factors that p...
Familial Adenomatous Polyposis (FAP) – Inheritedhttps://my.clevelandclinic.org/ccf/media...
Are there any Alternative Medical Practices you would Recommend? If Yes, Why?Consider taking turmeric. It has been st...
Colorectal Polyps in Childhood: Recent Advances in Genetics, Diagnosis, and Treatment of Polyps in the Large Intesti...PURPOSE OF REVIEW: Colorectal polyps ar...
Searchable Interface for Patient Education Information – Familial Adenomatous Polyposis (FAP)Familial Adenomatous Polyposis (FAP) is ...
Discrepancies in Biopsy Results in Pre- Versus Post-Endoscopic AmpullectomiesAbstract Purpose: Endoscopic ampullec...